{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:21:02Z","timestamp":1792102862064,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ijpharm.2014.03.048","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T13:16:03Z","timestamp":1395839763000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo"],"prefix":"10.1016","volume":"467","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-0094","authenticated-orcid":false,"given":"Annika","family":"Tuomela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooseppi","family":"Puranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"R\u00f6nkk\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Laaksonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giedrius","family":"Kalesnykas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Oksala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Ilkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Laru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouni","family":"Hirvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2014.03.048_bib0005","unstructured":"Alcon Laboratories, I., 2004. Product Information, CYCLOGYL\u00ae Ophthalmic Solution, 2004, 2014."},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.10.007","article-title":"Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling","volume":"149","author":"Ali","year":"2011","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0015","unstructured":"Allison, J., Elan sues Alcon over eye treatment Azopt., http:\/\/www.law360.com\/articles\/84323\/elan-sues-alcon-over-eye-treatment-azopt."},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0020","first-page":"614","article-title":"An SV40-immortalized human corneal epithelial cell line and its characterization","volume":"36","author":"Araki-Sasaki","year":"1995","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0025","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/02713680802447121","article-title":"Effect of daily prolonged ketamine anesthesia on intraocular pressure in monkeys","volume":"33","author":"Bunch","year":"2008","journal-title":"Current Eye Research"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0169-409X(93)90026-Z","article-title":"Swelling-controlled release in hydrogel matrices for oral route","volume":"11","author":"Colombo","year":"1993","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0035","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0039-6257(99)00108-3","article-title":"Preclinical overview of brinzolamide","volume":"44","author":"DeSantis","year":"2000","journal-title":"Survey of Ophthalmology"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/17425247.2.2.201","article-title":"Transporters and receptors in ocular drug delivery: opportunities and challenges","volume":"2","author":"Dey","year":"2005","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.exer.2011.03.016","article-title":"Effect of general anesthetics on IOP in elevated IOP mouse model","volume":"93","author":"Ding","year":"2011","journal-title":"Experimental Eye Research"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejps.2006.12.003","article-title":"Stable carbamazepine colloidal systems using the cosolvent technique","volume":"30","author":"Douroumis","year":"2007","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14712598.3.1.45","article-title":"Drug delivery to the retina: challenges and opportunities","volume":"3","author":"Duvvuri","year":"2003","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.2042-7158.2012.01587.x","article-title":"Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium","volume":"65","author":"El-Sousi","year":"2013","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0065","unstructured":"European Medicines Agancy - EMEA, 2008. Assessment Report for Azopt., http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000267\/WC500030365.pdf"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0070","unstructured":"European Medicines Agancy - EMEA, 2004. Product Information: Azopt., http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000267\/WC500030362.pdf"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0075","series-title":"US Food and Drug Administration: Inactive Ingredients for Approved Drug Products","author":"FDA","year":"2013"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0080","first-page":"961","article-title":"Drug delivery for posterior segment eye disease","volume":"41","author":"Geroski","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0085","series-title":"Pharmaceutical Preformulation and Formulation, A Practical Guide from Candidate Drug Selection to Commercial Dosage Form","first-page":"431","article-title":"Ophthalmic dosage forms","author":"Gibson","year":"2009"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0090","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Archives of Ophthalmology"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0095","first-page":"47","article-title":"Brinzolamide","volume":"26","author":"Hall","year":"1999"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jps.2600750316","article-title":"Effect of particle dissolution rate on ocular drug bioavailability","volume":"75","author":"Hui","year":"1986","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0105","unstructured":"Inoue, J., Shah, T., 2011. Ophthalmic composition US20110275617 A1, 10. November."},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0110","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3109\/02713689409015093","article-title":"The effect of a modified beta-cyclodextrin, SBE4-beta-CD, on the aqueous stability and ocular absorption of pilocarpine","volume":"13","author":"J\u00e4rvinen","year":"1994","journal-title":"Current Eye Research"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0115","first-page":"3415","article-title":"Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction","volume":"41","author":"Jia","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.neuroscience.2007.09.078","article-title":"The expression of heat shock protein 27 in retinal ganglion and glial cells in a rat glaucoma model","volume":"150","author":"Kalesnykas","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","article-title":"Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs","volume":"340","author":"Kassem","year":"2007","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1081\/DDC-120003445","article-title":"Ocular preparations: the formulation approach","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Development and Industrial Pharmacy"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/DDC-120002997","article-title":"Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Development and Industrial Pharmacy"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1389201053167158","article-title":"The impact of nanobiotechnology on the development of new drug delivery systems","volume":"6","author":"Kayser","year":"2005","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-5173(02)00686-5","article-title":"Formulation of amphotericin B as nanosuspension for oral administration","volume":"254","author":"Kayser","year":"2003","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jps.2600800113","article-title":"Limits on optimizing ocular drug delivery","volume":"80","author":"Keister","year":"1991","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/1389200033489488","article-title":"Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond","volume":"4","author":"Koevary","year":"2003","journal-title":"Current Drug Metabolism"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0160","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.carbpol.2010.06.030","article-title":"The influence of HPMC substitution pattern on solid-state properties","volume":"82","author":"Larsson","year":"2010","journal-title":"Carbohydrate Polymers"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2011.03.050","article-title":"Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling","volume":"411","author":"Liu","year":"2011","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0170","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The use of mucoadhesive polymers in ocular drug delivery","volume":"57","author":"Ludwig","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0928-0987(02)00057-X","article-title":"Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen","volume":"16","author":"Pignatello","year":"2002","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","author":"Quigley","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.supflu.2008.04.010","article-title":"Supercritical fluid assisted production of HPMC composite microparticles","volume":"46","author":"Reverchon","year":"2008","journal-title":"The Journal of Supercritical Fluids"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0195","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery","volume":"13","author":"Sahoo","year":"2008","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0200","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jnoncrysol.2010.12.031","article-title":"Effects of calcium salts on thermal characteristics of hydroxypropyl methylcellulose films","volume":"357","author":"Sakata","year":"2011","journal-title":"Journal of Non-Crystalline Solids"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0205","unstructured":"Scheve, S., Riddle, R., Siebman, C., Biotech & Pharma Patent Law: Civil action no 4.09-CV-32, demand for jury trial: Elan Pharma International (Plaintiff) vs. Alcon Laboratories Inc. and Alcon Manufacturing, LTD., http:\/\/patentdocs.typepad.com\/files\/elan-v-alcon.pdf"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0210","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/jps.20979","article-title":"Effect of polymer molecular weight on the production of drug nanoparticles","volume":"96","author":"Sepassi","year":"2007","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00112-0","article-title":"Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)","volume":"48","author":"Siepmann","year":"2001","journal-title":"Advances in Drug Delivery Reviews"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0220","first-page":"1541","article-title":"Basics of ocular drug delivery","volume":"4","author":"Tangri","year":"2011","journal-title":"International Journal of Research in Pharmaceutical and Biomedical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0225","first-page":"8","article-title":"Modern delivery systems for ocular drug formulations: a comparative overview w. r. t conventional dosage form","volume":"2","author":"Thakur","year":"2011","journal-title":"International Journal of Research in Pharmaceutical and Biomedical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00003226-199603000-00003","article-title":"Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren\u2019s syndrome","volume":"15","author":"Toda","year":"1996","journal-title":"Cornea"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0928-0987(03)00173-8","article-title":"Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model","volume":"20","author":"Toropainen","year":"2003","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0240","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-5173(90)90215-P","article-title":"Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits","volume":"61","author":"Urtti","year":"1990","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0245","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1208\/s12249-013-9997-2","article-title":"Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation","volume":"14","author":"Wu","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0250","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejps.2010.04.006","article-title":"Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability","volume":"40","author":"Xia","year":"2010","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ijpharm.2014.03.048_bib0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijpharm.2012.09.020","article-title":"Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation\/homogenization based on acid\u2013base neutralization","volume":"438","author":"Xu","year":"2012","journal-title":"International Journal of Pharmaceutics"}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517314002038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517314002038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T12:55:45Z","timestamp":1538744145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517314002038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":51,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0378517314002038"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2014.03.048","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2014.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}